Rgenta Therapeutics to Present Phase 1 Clinical Data on RNA-Targeting Cancer Drug RGT-61159 at ASCO 2026
核心洞察
Rgenta Therapeutics (搜索) will present clinical data from its ongoing Phase 1a/b study of RGT-61159, an oral MYB (搜索) splicing modulator, at the 2026 ASCO Annual Meeting in Chicago.
RGT-61159 is designed to specifically modulate splicing of the transcription factor MYB (搜索), resulting in inhibition of the oncogenic MYB protein in cancer cells that overexpress it.
The multi-center, open-label Phase 1a/b clinical trial is evaluating RGT-61159 in patients with advanced relapsed or refractory adenoid cystic carcinoma (搜索) or colorectal cancer (搜索).
Rgenta Therapeutics (搜索), a clinical-stage biotechnology company developing oral small molecules targeting RNA regulation, announced that clinical data from its ongoing Phase 1a/b study of RGT-61159 will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The poster presentation will showcase results from the company's novel oral MYB (搜索) splicing modulator in patients with adenoid cystic carcinoma (搜索) (ACC) or colorectal cancer (搜索) (CRC).
Novel RNA-Targeting Mechanism
RGT-61159 represents a new class of oral small molecules designed to specifically modulate splicing of the transcription factor MYB (搜索), resulting in inhibition of the oncogenic MYB protein and potential cell death in cancer cells that overexpress this protein. The drug targets MYB, which acts as a master regulator of cell proliferation, self-renewal, and differentiation processes.
The therapeutic approach addresses a significant unmet need, as MYB (搜索)'s aberrant expression has been demonstrated across multiple forms of human cancer including adenoid cystic carcinoma (搜索), acute myeloid leukemia (搜索) (AML), T-cell acute lymphoblastic leukemia (搜索) (T-ALL), colorectal cancer (搜索), small cell lung cancer (搜索) (SCLC) and breast cancer (搜索).
Clinical Trial Design and Objectives
Rgenta is currently evaluating RGT-61159 in a multi-center, open-label Phase 1a/b clinical trial in patients with advanced relapsed or refractory ACC or CRC. The study is designed to evaluate multiple parameters including safety, tolerability, pharmacokinetics, target engagement, and clinical efficacy of RGT-61159 in the specified patient populations.
ASCO Presentation Details
The clinical data will be presented during a poster session titled "Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology" on May 30, 2026, from 1:30 to 4:30 p.m. CDT at poster board 226. The presentation, titled "A Phase 1a/b Study of RGT-61159, An Oral MYB (搜索) Splicing Modulator, in Patients with Advanced Adenoid Cystic Carcinoma (搜索) and Colorectal Cancer (搜索)," has been assigned abstract number 3089.
Platform Technology Approach
Rgenta Therapeutics (搜索) has developed a proprietary platform that mines genomics data to identify targetable RNA processing events and design small-molecule glues to modulate interactions among the spliceosome, regulatory proteins, and RNAs. This approach aims to unlock the therapeutic potential of historically undruggable targets in human diseases, with an initial focus on oncology and neurological disorders.